While many of these clinical trials were deemed unsuccessful after failing to result in PR or CR, it is important to note that a significant portion of patients observed stable disease (SD) for a significant period of time, indicating that blocking the PI3K pathway inhibited TNBC tumor growth. Here, PIK3CA is linked to neoplasm.